Core Viewpoint - The company, Stone Four Pharmaceutical Group, announced its intention to bid for 14 specifications of 12 products in China's 11th national centralized drug procurement scheduled for October 27, 2025 [1] Product Summary - The products intended for bidding include: - Dihydrocodeine Injection (2ml: 0.3g) [1] - Formoterol Fumarate Inhalation Solution (2ml: 20μg) [1] - Fluvoxamine Maleate Tablets (100mg and 50mg) [1] - Chlorzoxazone Injection (8mg) [1] - Adrenaline Hydrochloride Injection (1ml: 1mg) [1] - Bromhexine Hydrochloride Injection (2ml: 4mg) [1] - Compound Electrolyte Injection (500ml) [1] - Compound Electrolyte Injection II (500ml and 1000ml) [1] - Nicorandil Tablets (5mg) [1] - Salbutamol Sulfate Injection (1ml: 0.5mg) [1] - Benidipine Hydrochloride Tablets (8mg) [1] - Sodium Bicarbonate Injection (50ml: 4.2g) [1]

本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 全國藥品集中採購擬中選結果 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 於二零二五年十月二十七日的中國第十一批全國藥品集中採購招標中，本集團共十二個產品十 四個品規分別擬中標：二羥丙茶鹼注射液(2ml:0.3g)、富馬酸福莫特羅吸入溶液(2ml:20µg)、 馬來酸氟伏沙明片(100mg 及50mg)、注射用氯諾昔康(8mg)、鹽酸腎上腺素注射液(1ml:1mg)、 鹽酸溴己新注射液(2ml:4mg)、複方電解質注射液(500ml)、複方電解質注射液(II)(500ml 及 1000ml)、尼可地爾片(5mg)、硫酸沙丁胺醇注射液(1ml:0.5mg)、鹽酸貝尼地平片(8mg)及碳酸 氫鈉注射液 (50ml:4.2g)。 承董事局命 執行董事兼公司秘書 周興揚 香港， ...

Core Viewpoint - Recently, Shijiazhuang Four Drug Group announced the approval of its generic version of Benidipine Hydrochloride Tablets, which is considered equivalent to the original product. According to MoSheng Pharmaceutical data, over 20 pharmaceutical companies have received approval for this product so far [1][10]. Group 1: Product Overview - Benidipine Hydrochloride Tablets are calcium channel blockers that selectively inhibit calcium ion influx across vascular smooth muscle cell membranes, thereby reducing peripheral vascular resistance, which helps in lowering blood pressure and alleviating angina [4]. - The total sales of Benidipine Hydrochloride Tablets in the full terminal hospital market are expected to exceed 2 billion yuan in 2024, making it one of the top 10 cardiovascular system drugs in terms of sales [4][5]. Group 2: Market Competition - In the 2024 full terminal hospital market, Benidipine Hydrochloride Tablets exhibit a three-way competitive landscape. Yangtze River Pharmaceutical holds the leading market share at 27.61%, followed by North China Pharmaceutical with 25.24%, and Nanchang Hongyi Pharmaceutical at 16.31% [6]. Group 3: Industry Participation - Currently, 22 companies, including Shijiazhuang Four Drug, North China Pharmaceutical, and Yangtze River Pharmaceutical Group, have received approval for Benidipine Hydrochloride Tablets, with 4 companies participating in the eighth batch of centralized procurement [10]. - In terms of generic drug development, over 30 companies, including Jiangsu Wango Pharmaceutical and Hunan Jiudian Pharmaceutical, are in the process of applying for the generic version under category 4 [10][13].

Summary of Key Points Core Viewpoint - On October 21, 32 Hong Kong-listed companies conducted share buybacks, totaling 14.32 million shares and an aggregate amount of HKD 58.19 million [1]. Group 1: Buyback Details - The company YunGongChang repurchased 2.10 million shares for HKD 8.22 million, with a highest price of HKD 3.980 and a lowest price of HKD 3.880, bringing its total buyback amount for the year to HKD 119 million [1][2]. - LianYiRong Technology-W repurchased 2.38 million shares for HKD 7.45 million, with a highest price of HKD 3.180 and a lowest price of HKD 3.100, totaling HKD 218 million in buybacks for the year [1][2]. - Mengniu Dairy repurchased 0.50 million shares for HKD 7.26 million, with a highest price of HKD 14.550 and a lowest price of HKD 14.460, accumulating HKD 451 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on October 21 was from YunGongChang at HKD 8.22 million, followed by LianYiRong Technology-W at HKD 7.45 million, and Mengniu Dairy also featured prominently [1][2]. - In terms of share quantity, LianYiRong Technology-W led with 2.38 million shares repurchased, followed by ShiSiYao Group and YunGongChang, each with 2.10 million shares [1][2]. Group 3: Additional Insights - KJ Pharma-B conducted its first buyback of the year, while Mengniu Dairy has made multiple buybacks totaling HKD 451 million [2]. - A detailed table of buybacks on October 21 includes various companies, their respective share counts, amounts, and price ranges, highlighting the active buyback environment in the Hong Kong market [2][3].

Group 1 - Multiple companies conducted share buybacks on October 21, 2025, with a total of 30 companies listed [1] - The largest buyback was by Cloud Factory (N23027), repurchasing 2.1 million shares for a total of 8.22 million yuan [1][2] - Other notable buybacks include Linklogis Technology (W09959) with 2.38 million shares for 7.45 million yuan and Mengniu Dairy (02319) with 500,000 shares for 7.26 million yuan [2] Group 2 - Cumulative buyback amounts for the year show Cloud Factory (N23027) has repurchased a total of 26.62 million shares, representing 5.786% of its total share capital [2] - Linklogis Technology (W09959) has repurchased 67.82 million shares, accounting for 3.174% of its total share capital [2] - Other companies with significant cumulative buybacks include Stone Four Pharmaceutical (02005) with 39.20 million shares (1.328%) and Kangchen Pharmaceutical (01681) with 6.50 million shares (7.637%) [2][3]

备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 股票名称 机构名称 性质 变动前持股 变动后持股 持股比 石四药集团(02005) 曲继广 好仓 12.15 亿股 12.17 亿股 41.22%(最新) 41.15%(前次) () 黄晓凌 好仓 11.00 万股 0股 0%(最新) 0.07%(前次) 智通财经APP获悉，石四药集团(02005)、()于2025年10月22日进行了最新股东权益披露。 ...

Major Events - Guanghe Tong (00638) has set the offer price at HKD 21.5 per share, with the public offering receiving a subscription rate of 550.99 times [1] - China Biologic Products (01177) announced the Phase III study data of Kymriah combined with Fluvestrant for the first-line treatment of advanced breast cancer will be presented at ESMO 2025 [1] - Derun Holdings (01709) plans to conduct a placement of new shares at a discount of approximately 11.34%, aiming to raise about HKD 761 million [1] - New World Development (00017) clarified media reports, stating that it has not undertaken any debt management projects regarding perpetual and other debt securities [1] - China Shenhua (01088) reported that Unit 4 of the Jiujiang Phase II project has successfully completed a 168-hour trial run [1] - Jingwei TianDi (02477) has acquired a TCSP licensed company and launched a new feature called FOPAY [1] - Rongzun International Holdings (01780) announced that its controlling shareholder intends to place up to 60% of the company's shares, reducing their stake to 15% [1] Financial Performance - Pop Mart (09992) reported a year-on-year revenue growth of 245%-250% for the third quarter [2] - China Telecom (00728) recorded a profit attributable to shareholders of RMB 30.8 billion for the first three quarters, reflecting a year-on-year increase of 5.0% [2] - Luk Fook Holdings (00590) reported that its overall retail value, retail income, and same-store sales for the second quarter exceeded the first quarter, increasing by 18%, 15%, and 10% respectively [2] - Minmetals Resources (01208) produced a total of 127,000 tons of copper in the third quarter, marking an 11% year-on-year increase [2] - Datang Power (00991) achieved a total electricity generation of approximately 2,062.41 billion kilowatt-hours in the first three quarters, up about 2.02% year-on-year [2] - Far East Horizon (03360) reported an increase in profit attributable to ordinary shareholders for the first three quarters [2] - China General Nuclear Power Corporation (01164) produced a total of 644.3 tons of natural uranium in the third quarter [2]

Core Points - The company, Shijiazhuang Pharmaceutical Group, announced a share buyback on October 21, purchasing 2.1 million shares at a price range of HKD 2.880 to HKD 2.920, totaling HKD 6.0813 million [2] - The stock closed at HKD 2.890 on the same day, reflecting a 1.05% increase, with a total trading volume of HKD 22.8912 million [2] - Year-to-date, the company has conducted 16 buybacks, acquiring a total of 45.1 million shares for a cumulative amount of HKD 133 million [2] Buyback Details - The buyback details include various dates, number of shares repurchased, highest and lowest buyback prices, and total buyback amounts, showcasing a consistent strategy to enhance shareholder value [2] - For instance, on October 14, the company repurchased 210,000 shares at a maximum price of HKD 2.940, totaling HKD 6.0908 million [2] - The highest buyback price recorded was HKD 3.440 on April 2, with a total of 280,000 shares repurchased for HKD 9.5882 million [2]

石四药集团(02005)发布公告，于2025年10月21日，该公司斥资608.13万港元回购210万股股份，每股回 购价格为2.88-2.92港元。 ...

Core Viewpoint - The company, Stone Four Pharmaceutical Group, announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 2.1 million shares at a total cost of HKD 6.0813 million [1] - The buyback price per share is set between HKD 2.88 and HKD 2.92 [1] - The buyback is scheduled to take place on October 21, 2025 [1]